Yuchuan Yang , Xiaoying Xu

Biotechnology Research Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 5   
Received: 06 Aug., 2024    Accepted: 13 Sep., 2024    Published: 14 Oct., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study explores the significance of early diagnosis of Alzheimer's disease (AD) and its impact on patients and their families. Through detailed clinical case analyses, the study presents the clinical manifestations of early AD, diagnostic tools, and the latest advancements in biomarkers. It covers topics such as neuropsychological assessments, standardized cognitive tests, imaging techniques (e.g., MRI and PET scans), and the application of biomarkers in blood and cerebrospinal fluid. The discussion also includes genetic factors, pharmacological and non-pharmacological intervention strategies, and the psychological, emotional, and social effects of early diagnosis on patients and their families. By systematically summarizing the current research progress in early diagnosis, this study aims to provide a reference for clinical practice and propose recommendations for future research and management strategies.

Alzheimer's disease; Early diagnosis; Biomarkers; Neuropsychological assessment; Genetic factors